Molecular Approaches to Heart Failure Therapy

  • Gerd Hasenfuss
  • Eduardo Marbán

Table of contents

  1. Front Matter
    Pages I-X
  2. G. Hasenfuss, E. Marbán
    Pages 1-3
  3. M. J. Lohse, S. Engelhardt
    Pages 26-38
  4. F. Del Monte, S. E. Harding, R. J. Hajjar
    Pages 53-68
  5. G. Inesi, M. Cavagna, J. M. O’donnell, C. Sumbilla, L. Zhong, H. Ma et al.
    Pages 76-88
  6. J. Prestle, P. M. L. Janssen, A. Janssen, G. Hasenfuss
    Pages 89-99
  7. J. K. Donahue
    Pages 100-111
  8. P. M. L. Janssen, S. E. Lehnart, J. K. Donahue, J. Prestle, E. Marbán, G. Hasenfuss
    Pages 112-125
  9. W.-M. Franz, O. J. Müller, H. A. Katus, G. von Degenfeld, G. Steinbeck, P. Boekstegers
    Pages 126-143
  10. T. Eschenhagen, C. Fink, T. Rau, U. Remmers, J. Weil, W. H. Zimmermann et al.
    Pages 144-156
  11. D. J. Beuckelmann, L. Priebe, U. C. Hoppe
    Pages 157-179
  12. U. C. Hoppe, H. B. Nuss, B. O’Rourke, E. Marbán, D. C. Johns
    Pages 180-196
  13. J. Holtz, M. Tostlebe, D. Darmer
    Pages 197-231
  14. A. Haunstetter, S. Izumo
    Pages 232-246
  15. D. B. Sawyer, W. S. Colucci
    Pages 262-284
  16. H. Reinecke, G. H. Macdonald, S. D. Hauschka, C. E. Murry
    Pages 316-332
  17. K. B. S. Pasumarthi, L. J. Field
    Pages 333-351
  18. Back Matter
    Pages 353-357

About this book


G. HASENFUSS, E. MARBAN Heart failure embodies the central irony of modern medicine. As we have become increasingly adept at treating the major proximate causes of death in Western society, we have effectively converted acute illness into chronic malady. The last twenty years have witnessed a revolution in the treatment of acute coronary syndromes, myocardial infarction in particular. Patients who reach the hospital now have every expectation of leaving alive, but not necessarily well. Our ability to blunt the edge of ischemic insults has en­ gendered new problems: a new cohort of patients whose hearts function well enough to enable short-term survival, but at the cost of decreased ex­ ercise tolerance, dyspnea and increased long-term mortality. The irony is compounded by our increasingly sophisticated pharmacopeia for the treat­ ment of heart failure, which, by slowing the progression of ventricular dys­ function, has created a chronic illness. The fact of its chronicity makes heart failure no less deadly. In symptomatic patients, mortality exceeds 5-10% per year even with the best contemporary therapy. Not all heart failure is ischemic, of course, but the final common phenotype is eerily concordant regardless of the proximate cause. No wonder, then, that heart failure is the leading cause of hospitalization in America and in Western Europe and that the prevalence of the disease continues to rise. Drugs have indeed revolutionized heart failure therapy, ACE inhibitors and beta-adrenergic blockers having the most outstanding records to date.


arrhythmia cardiac function gene therapy heart heart failure molecular approaches to heart failure myocardial gene transfer techniques myocardial infarction pathophysiology in heart failure physiology protein regulation transplantation

Editors and affiliations

  • Gerd Hasenfuss
    • 1
  • Eduardo Marbán
    • 2
  1. 1.Zentrum Innere Medizin, Abt. Kardiologie und PneumologieGeorg-August-Universität GöttingenGöttingenGermany
  2. 2.Section of Molecular and Cellular CardiologyThe Johns Hopkins UniversityBaltimoreUSA

Bibliographic information

  • DOI
  • Copyright Information Steinkopff Verlag Darmstadt 2000
  • Publisher Name Steinkopff, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-63332-4
  • Online ISBN 978-3-642-57710-9
  • Buy this book on publisher's site